SeaStar Medical Holding Corporation (ICU), a commercial-stage medical device company, today announced the activation of its 13th active site for the NEUTRALIZE-AKI pivotal trial.
The NEUTRALIZE-AKI trial is evaluating the safety and efficacy of the company's proprietary therapeutic Selective Cytopheretic Device (SCD) in 200 adult patients with acute kidney injury in the intensive care unit (ICU) receiving continuous renal replacement therapy (CRRT).
The 13th active site for the NEUTRALIZE-AKI pivotal trial to be activated is the Sentara Norfolk General Hospital in Norfolk, Virginia.
Last month, nine critically ill adult acute kidney injury (AKI) patients were enrolled in the trial, increasing the total enrollment to 65 participants.
AKI, a condition that can lead to hyperinflammation, is marked by a sudden and temporary loss of kidney function.
Eric Schlorff, SeaStar Medical CEO, said, "Given the addressable adult AKI population of approximately 210,000 patients in the U.S. each year, we estimate annual peak sales of approximately $1 billion for the SCD in this indication.
ICU closed Tuesday's trading at $2.37, down by 0.42 percent on Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.